Results refer to phases 1 and 2, but are still preliminary; vaccine is tested in 7 thousand volunteers in Brazil already in phase 3
A light at the end of the pandemic. According to preliminary results, the vaccine developed by the Johnson & Johnson group against the new coronavirus (Covid-19) is safe and induces an immune response in the body after a single application.
The results, released last Friday (25) in an online repository, are part of the participants in phases 1 and 2, which were conducted jointly. However, it is worth mentioning that they have not yet been reviewed by other scientists – a necessary methodology for publication in a scientific journal.
The vaccine, which has an official name is Ad26.COV2.S, was developed by Janssen Pharmaceuticals, which belongs to the Johnson & Johnson group. The immunizer is one of those being tested in Brazil, with about 7 thousand participants. Worldwide, 60,000 volunteers are helping to better understand the effects of the vaccine.